SuperworthNexgel NXGL
- Market cap
- $2.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Nexgel's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2M+115% | $1.1M+107% | $1.3M+104% | $1.4M+23% | $2.9M+141% | $3M+181% | $2.8M+122% | $2.9M+100% | $2.9M−0% | n/a | $2.6M−6% | $3.7M+28% | |
| Cost of revenue | $877K+109% | $924K+89% | $1.1M+63% | $1.1M+16% | $1.8M+104% | $2.3M+145% | $1.6M+46% | $1.6M+42% | $1.7M−5% | n/a | $1.6M−2% | $2.6M+59% |
| Gross profit | $344K+132% | $158K+339% | $160K | $293K+67% | $1.2M+236% | $779K+393% | $1.2M+643% | $1.3M+329% | $1.2M+8% | n/a | $1.1M−11% | $1.1M−12% |
| R&D | $6K−97% | $13K−67% | $2K−93% | $76K+38% | $0 | $0 | $1K−50% | $0 | $7K | n/a | n/a | $20K |
| SG&A | $950K−4% | $1.4M+75% | $1M+29% | $1.3M+44% | $1.9M+105% | $1.6M+19% | $2M+91% | $1.9M+49% | $2M+1% | n/a | $2M+3% | $3.6M+90% |
| −$612K−41% | −$1.2M+56% | −$871K−1% | −$1.1M+38% | −$788K+29% | −$841K−31% | −$777K−11% | −$636K−40% | −$725K−8% | n/a | −$958K+23% | −$2.5M+294% | |
| Interest expense | $3K−99% | $2K+0% | $15K+1400% | $29K+222% | −$20K | $14K+600% | n/a | $21K−28% | $10K | n/a | n/a | n/a |
| Pre-tax income | −$552K−55% | −$1.2M+83% | −$905K+12% | −$979K+53% | −$754K+37% | −$824K−31% | −$678K−25% | −$640K−35% | −$647K−14% | n/a | −$871K+29% | −$3.6M+463% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$550K−55% | −$1.1M+69% | −$853K+5% | −$885K+27% | −$693K+26% | −$850K−23% | −$712K−17% | −$665K−25% | −$653K−6% | −$970K+14% | −$927K+30% | −$3.6M+447% |
| −$2.00−55% | −$3.80+58% | −$2.80−7% | −$2.80+17% | −$2.20+10% | −$2.40−37% | −$1.80−36% | −$1.80−36% | −$1.60−27% | −$2.40+0% | −$2.20+22% | −$8.00+344% | |
| 285.7K+3% | 286.1K+3% | 299.1K+7% | 312.7K+11% | 328.5K+15% | 360.9K+26% | 382.3K+28% | 382.7K+22% | 398.6K+21% | 407.1K+13% | 410.2K+7% | 450.7K+18% |
Revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
SG&A: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Operating income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
Net income: Q1 FY18 and Q1 FY19: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 8 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q1 FY19: share-days: the 6-month average less the second quarter's.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Nexgel's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NXGLNexgel | $2.5M | n/m | n/a | n/m | n/m | n/m | |
| OXBROXBRIDGE RE HOLDINGS | $7.7M | 47.5× | 9.6× | 2.8× | +40% | 4.7% | |
| EDUCEducational Development | $8.7M | 5.4× | 11.3× | 0.4× | −32% | 8.6% | |
| GTIMGood Times Restaurants | $13.6M | 6.1× | 13.6× | 0.1× | −6% | 1.7% | |
| MDRRMedalist Diversified | $15.4M | 2.5× | 3.0× | 1.6× | −1% | 80.2% | |
| BCGBinah Capital | $18.2M | 6.7× | 20.8× | 0.1× | +8% | 2.2% | |
| VIPVulcan Infrastructure & Power | $19.6M | 17.9× | 24.4× | 0.4× | −14% | 1.0% | |
| MXCMexco Energy | $20.5M | 13.4× | 13.3× | 3.0× | −9% | 23.3% | |
| CKXCKX Lands | $21.5M | 7.4× | 32.6× | 31.0× | −17% | n/m | |
| MSGMMotorsport Games | $22.5M | 11.4× | 11.5× | 1.5× | +79% | 16.2% | |
| ATCHAtlasClear | $24M | 15.8× | 17.5× | 1.2× | +85% | 9.8% | |
| Peer median | $18.9M | 9.4× | 13.4× | 1.4× | −3% | 8.6% |
More on Nexgel
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .